Grifols (NASDAQ:GRFS) Shares Gap Down to $7.18

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $7.18, but opened at $6.85. Grifols shares last traded at $6.95, with a volume of 107,950 shares.

Grifols Trading Down 4.7 %

The stock has a market cap of $4.70 billion, a P/E ratio of 6.75 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 1.29. The firm’s 50 day moving average price is $7.41 and its 200-day moving average price is $7.28.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The company had revenue of $1.96 billion for the quarter. As a group, equities research analysts forecast that Grifols, S.A. will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On Grifols

Several hedge funds and other institutional investors have recently modified their holdings of GRFS. Capital World Investors increased its stake in shares of Grifols by 4.9% in the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares in the last quarter. Brandes Investment Partners LP lifted its position in shares of Grifols by 22.2% in the fourth quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock valued at $156,245,000 after acquiring an additional 2,454,730 shares in the last quarter. Black Creek Investment Management Inc. raised its stake in Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares during the period. First Trust Advisors LP lifted its holdings in Grifols by 6.9% in the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock worth $54,156,000 after purchasing an additional 302,380 shares in the last quarter. Finally, Norges Bank bought a new position in Grifols in the 4th quarter worth approximately $26,137,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.